Document is current

Article History

Received: 4 January 2024

Revised: 17 May 2024

Accepted: 20 May 2024

First Online: 17 June 2024

Competing interests

: Dr. Abdallah has served as a consultant, speaker, and/or on advisory boards for Genentech, Janssen, Lundbeck, FSV7, and Aptinyx, and editor of <i>Chronic Stress</i> for Sage Publications, Inc.; Filed a patent for using mTORC1 inhibitors to augment the effects of antidepressants (filed on Aug 20, 2018). Dr. Krystal is a consultant for AbbVie, Inc., Amgen, Astellas Pharma Global Development, Inc., AstraZeneca Pharmaceuticals, Biomedisyn Corporation, Bristol-Myers Squibb, Eli Lilly and Company, Euthymics Bioscience, Inc., Neurovance, Inc., FORUM Pharmaceuticals, Janssen Research & Development, Lundbeck Research USA, Novartis Pharma AG, Otsuka America Pharmaceutical, Inc., Sage Therapeutics, Inc., Sunovion Pharmaceuticals, Inc., and Takeda Industries; is on the Scientific Advisory Board for Lohocla Research Corporation, Mnemosyne Pharmaceuticals, Inc., Naurex, Inc., and Pfizer; is a stockholder in Biohaven Pharmaceuticals; holds stock options in Mnemosyne Pharmaceuticals, Inc.; holds patents for Dopamine and Noradrenergic Reuptake Inhibitors in Treatment of Schizophrenia, U.S. Patent No. 5,447,948 (issued Sep 5, 1995), and Glutamate Modulating Agents in the Treatment of Mental Disorders, U.S. Patent no. 8,778,979 (issued Jul 15, 2014); and filed a patent for Intranasal Administration of Ketamine to Treat Depression – U.S. Application No. 14/197,767 (filed on Mar 5, 2014); U.S. application or Patent Cooperation Treaty international application No. 14/306,382 (filed on Jun 17, 2014). Filed a patent for using mTORC1 inhibitors to augment the effects of antidepressants (filed on Aug 20, 2018). Dr. L. Averill has served as a consultant, speaker, and/or on advisory boards for Transcend Therapeutics, Beond, Reason for Hope, Source Research Foundation, Guidepoint, Techspert, and owns NPSYT, PLLC. All other co-authors declare no conflict of interest.